Administration de liquides dans l'acidocétose (BOIRE) (DRINK)
Comparaison de la solution saline et du Ringer Lactate chez les patients atteints d'acidocétose diabétique sévère (DRINK) : un essai contrôlé randomisé en double aveugle
Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Mathieu JOZWIAK, MD PhD
- Numéro de téléphone: +33492035510
- E-mail: jozwiak.m@chu-nice.fr
Lieux d'étude
-
-
-
Nice, France
- Recrutement
- CHU NICE
-
Contact:
- MATHIEU JOZWIAK, MD PhD
- Numéro de téléphone: +33492035510
- E-mail: jozwiak.m@chu-nice.fr
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Admission to emergency department or direct admission to ICU
- Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
- Blood or capillary glucose > 11 mmol/L
- Ketonemia or ketonuria > 0
- Venous or arterial pH < 7.30 or venous or arterial bicarbonate < 15 mmol/L
- Volume of fluid administered before inclusion <1L
Exclusion Criteria:
- Patients <18 years
- Pregnant women
- Patients under protection
- Patients with a decision to withdraw life-sustaining therapy
- Contraindication to isotonic saline or Ringer Lactate
- Non-affiliation to social security
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: Solution saline isotonique
|
Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:
|
|
Expérimental: Sonnerie Lactate
|
Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Resolution of diabetic ketoacidosis
Délai: at 24 hours
|
Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis. Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission :
|
at 24 hours
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Speed of resolution of metabolic disorders
Délai: at 48 hours
|
Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis. Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria:
|
at 48 hours
|
|
Time of resolution of metabolic disorders
Délai: at 48 hours
|
Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis. Time (in hours) from ICU admission to obtain one of the following three criteria:
|
at 48 hours
|
|
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution
Délai: through the end of study average 24 months
|
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of serious metabolic disorders during ICU stay, defined as :
|
through the end of study average 24 months
|
|
Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications
Délai: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of adverse events during ICU stay, defined as :
|
at 28 days
|
|
Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications
Délai: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of adverse events during ICU stay, defined as :
|
at 28 days
|
|
Assess the impact of Ringer lactate compared with isotonic saline on renal complications
Délai: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Measure acute renal failure with KDIGO classification. The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe. No cut-off for the study |
at 28 days
|
|
Assess the impact of Ringer lactate compared with isotonic saline on neurological complications
Délai: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study. |
at 28 days
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 22-API-03
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .